Summary

The global market for Oligonucleotide Conjugates was estimated to be worth US$ 169.2 million in 2024 and is forecast to a readjusted size of US$ 1,768.8 million by 2031 with a CAGR of 40.36% during the forecast period 2025-2031.
North American market for Oligonucleotide Conjugates was valued at $ 72.98 million in 2024 and will reach $ 719.9 million by 2031, at a CAGR of 39.28% during the forecast period of 2025 through 2031.
Asia-Pacific market for Oligonucleotide Conjugates was valued at $ 43.89 million in 2024 and will reach $ 542.67 million by 2031, at a CAGR of 43.72% during the forecast period of 2025 through 2031.
Europe market for Oligonucleotide Conjugates was valued at $ 45.29 million in 2024 and will reach $ 443.26 million by 2031, at a CAGR of 38.89% during the forecast period of 2025 through 2031.
The global key companies of Oligonucleotide Conjugates include WuXi TIDES, Bachem, Lonza, BioSpring, GenScript, Medtide (CPC Scientific), Pharmaron, Bio-Synthesis Inc, and Kaneka Corporation (Eurogentec), etc. in 2024, the global five largest players hold a share approximately 72% in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Conjugates, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oligonucleotide Conjugates by region & country, by Type, and by Application.
The Oligonucleotide Conjugates market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Conjugates.
Market Segmentation
By Company
 WuXi TIDES
 Bachem
 Lonza
 BioSpring
 GenScript
 Medtide(CPC Scientific)
 Kaneka Corporation(Eurogentec)
 Olon(GTP Bioways)
 Abzena
 3PBIOVIAN
 Bio-Synthesis Inc
 ChemExpress
 Creative Biolabs
 HitGen
 Pharmaron
 Suzhou Biosyntech
 Creative Biogene (IntegrateRNA)

Segment by Type
 Oligonucleotide-Peptide
 Oligonucleotide-Antibody
 Oligonucleotide-GalNAc
 Oligonucleotide-Lipid
 Other

Segment by Application
Gene Therapy
 Drug Delivery
 Vaccine Development

By Region
North America
 United States
 Canada

 Asia-Pacific
 China
 Japan
 South Korea
 Southeast Asia
 India
 Australia
 Rest of Asia-Pacific

Europe
 Germany
 U.K.
 Switzerland
 Belgium
 France
 Rest of Europe

 Latin America
 Mexico
 Brazil
 Rest of Latin America

 Middle East & Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oligonucleotide Conjugates company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Oligonucleotide Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Oligonucleotide Conjugates in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview 1
1.1 Oligonucleotide Conjugates Product Introduction 1
1.2 Global Oligonucleotide Conjugates Market Size Forecast (2020-2031) 1
1.3 Oligonucleotide Conjugates Market Trends & Drivers 3
1.3.1 Oligonucleotide Conjugates Industry Trends 3
1.3.2 Oligonucleotide Conjugates Market Drivers & Opportunity 4
1.3.3 Oligonucleotide Conjugates Market Challenges 5
1.3.4 Oligonucleotide Conjugates Market Restraints 6
1.4 Assumptions and Limitations 6
1.5 Study Objectives 7
1.6 Years Considered 8
2 Competitive Analysis by Company 9
2.1 Global Oligonucleotide Conjugates Players Revenue Ranking (2024) 9
2.2 Global Oligonucleotide Conjugates Revenue by Company (2020-2025) 10
2.3 Key Companies Oligonucleotide Conjugates Product Offered 12
2.4 Key Companies Time to Establish 13
2.5 Oligonucleotide Conjugates Market Competitive Analysis 14
2.5.1 Oligonucleotide Conjugates Market Concentration Rate (2020-2025) 14
2.5.2 Global 5 and 10 Largest Companies by Oligonucleotide Conjugates Revenue in 2024 16
2.5.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Conjugates as of 2024) 17
2.6 Mergers & Acquisitions, Expansion 19
3 Segmentation by Type 22
3.1 Introduction by Type 22
3.1.1 Oligonucleotide-Peptide 22
3.1.2 Oligonucleotide-Antibody 22
3.1.3 Oligonucleotide-GalNAc 23
3.1.4 Oligonucleotide-Lipid 24
3.1.5 Other 25
3.2 Global Oligonucleotide Conjugates Sales Value by Type 26
3.2.1 Global Oligonucleotide Conjugates Sales Value by Type (2020 VS 2024 VS 2031) 26
3.2.2 Global Oligonucleotide Conjugates Sales Value, by Type (2020-2031) 28
3.2.3 Global Oligonucleotide Conjugates Sales Value, by Type (%) (2020-2031) 29
4 Segmentation by Application 30
4.1 Introduction by Application 30
4.1.1 Gene Therapy 30
4.1.2 Drug Delivery 30
4.1.3 Vaccine Development 30
4.2 Global Oligonucleotide Conjugates Sales Value by Application 31
4.2.1 Global Oligonucleotide Conjugates Sales Value by Application (2020 VS 2024 VS 2031) 31
4.2.2 Global Oligonucleotide Conjugates Sales Value, by Application (2020-2031) 33
4.2.3 Global Oligonucleotide Conjugates Sales Value, by Application (%) (2020-2031) 33
5 Segmentation by Region 35
5.1 Global Oligonucleotide Conjugates Sales Value by Region 35
5.1.1 Global Oligonucleotide Conjugates Sales Value by Region: 2020 VS 2024 VS 2031 35
5.1.2 Global Oligonucleotide Conjugates Sales Value by Region (2020-2025) 36
5.1.3 Global Oligonucleotide Conjugates Sales Value by Region (2026-2031) 36
5.1.4 Global Oligonucleotide Conjugates Sales Value by Region (%), (2020-2031) 37
5.2 North America 38
5.2.1 North America Oligonucleotide Conjugates Sales Value, 2020-2031 38
5.2.2 North America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031 39
5.3 Europe 40
5.3.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031 40
5.3.2 Europe Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031 41
5.4 Asia Pacific 42
5.4.1 Asia Pacific Oligonucleotide Conjugates Sales Value, 2020-2031 42
5.4.2 Asia Pacific Oligonucleotide Conjugates Sales Value by Region (%), 2024 VS 2031 43
5.5 South America 44
5.5.1 South America Oligonucleotide Conjugates Sales Value, 2020-2031 44
5.5.2 South America Oligonucleotide Conjugates Sales Value by Country (%), 2024 VS 2031 45
6 Segmentation by Key Countries/Regions 46
6.1 Key Countries/Regions Oligonucleotide Conjugates Sales Value Growth Trends, 2020 VS 2024 VS 2031 46
6.2 Key Countries/Regions Oligonucleotide Conjugates Sales Value, 2020-2031 47
6.3 United States 51
6.3.1 United States Oligonucleotide Conjugates Sales Value, 2020-2031 51
6.3.2 United States Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 52
6.3.3 United States Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 53
6.4 Europe 54
6.4.1 Europe Oligonucleotide Conjugates Sales Value, 2020-2031 54
6.4.2 Europe Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 55
6.4.3 Europe Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 56
6.5 China 57
6.5.1 China Oligonucleotide Conjugates Sales Value, 2020-2031 57
6.5.2 China Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 58
6.5.3 China Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 59
6.6 Japan 60
6.6.1 Japan Oligonucleotide Conjugates Sales Value, 2020-2031 60
6.6.2 Japan Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 61
6.6.3 Japan Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 62
6.7 South Korea 63
6.7.1 South Korea Oligonucleotide Conjugates Sales Value, 2020-2031 63
6.7.2 South Korea Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 64
6.7.3 South Korea Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 65
6.8 Australia 66
6.8.1 Australia Oligonucleotide Conjugates Sales Value, 2020-2031 66
6.8.2 Australia Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 67
6.8.3 Australia Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 68
6.9 India 69
6.9.1 India Oligonucleotide Conjugates Sales Value, 2020-2031 69
6.9.2 India Oligonucleotide Conjugates Sales Value by Type (%), 2024 VS 2031 70
6.9.3 India Oligonucleotide Conjugates Sales Value by Application, 2024 VS 2031 71
7 Company Profiles 72
7.1 WuXi TIDES 72
7.1.1 WuXi TIDES Profile 72
7.1.2 WuXi TIDES Main Business 73
7.1.3 WuXi TIDES Oligonucleotide Conjugates Products, Services and Solutions 74
7.1.4 WuXi TIDES Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 74
7.1.5 WuXi TIDES Recent Developments 75
7.2 Bachem 75
7.2.1 Bachem Profile 75
7.2.2 Bachem Main Business 76
7.2.3 Bachem Oligonucleotide Conjugates Products, Services and Solutions 77
7.2.4 Bachem Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 77
7.2.5 Bachem Recent Developments 77
7.3 Lonza 78
7.3.1 Lonza Profile 78
7.3.2 Lonza Main Business 79
7.3.3 Lonza Oligonucleotide Conjugates Products, Services and Solutions 79
7.3.4 Lonza Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 80
7.3.5 Lonza Recent Developments 80
7.4 BioSpring 81
7.4.1 BioSpring Profile 81
7.4.2 BioSpring Main Business 81
7.4.3 BioSpring Oligonucleotide Conjugates Products, Services and Solutions 82
7.4.4 BioSpring Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 83
7.4.5 BioSpring Recent Developments 83
7.5 GenScript 84
7.5.1 GenScript Profile 84
7.5.2 GenScript Main Business 85
7.5.3 GenScript Oligonucleotide Conjugates Products, Services and Solutions 85
7.5.4 GenScript Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 86
7.6 Medtide (CPC Scientific) 86
7.6.1 Medtide (CPC Scientific) Profile 86
7.6.2 Medtide (CPC Scientific) Main Business 87
7.6.3 Medtide (CPC Scientific) Oligonucleotide Conjugates Products, Services and Solutions 88
7.6.4 Medtide (CPC Scientific) Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025) 89
7.6.5 Medtide (CPC Scientific) Recent Developments 89
7.7 Kaneka Corporation (Eurogentec) 89
7.7.1 Kaneka Corporation (Eurogentec) Profile 89
7.7.2 Kaneka Corporation (Eurogentec) Main Business 90
7.7.3 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Products, Services and Solutions 91
7.7.4 Kaneka Corporation (Eurogentec) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 91
7.8 Olon (GTP Bioways) 92
7.8.1 Olon (GTP Bioways) Profile 92
7.8.2 Olon (GTP Bioways) Main Business 92
7.8.3 Olon (GTP Bioways) Oligonucleotide Conjugates Products, Services and Solutions 93
7.8.4 Olon (GTP Bioways) Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025) 94
7.8.5 Olon (GTP Bioways) Recent Developments 94
7.9 Abzena 94
7.9.1 Abzena Profile 95
7.9.2 Abzena Main Business 95
7.9.3 Abzena Oligonucleotide Conjugates Products, Services and Solutions 96
7.9.4 Abzena Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 96
7.10 3PBIOVIAN 97
7.10.1 3PBIOVIAN Profile 97
7.10.2 3PBIOVIAN Main Business 98
7.10.3 3PBIOVIAN Oligonucleotide Conjugates Products, Services and Solutions 98
7.10.4 3PBIOVIAN Oligonucleotide Conjugates Revenue (US$ Million) & (2022-2025) 99
7.11 Bio-Synthesis Inc 99
7.11.1 Bio-Synthesis Inc Profile 99
7.11.2 Bio-Synthesis Inc Main Business 100
7.11.3 Bio-Synthesis Inc Oligonucleotide Conjugates Products, Services and Solutions 100
7.11.4 Bio-Synthesis Inc Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 102
7.12 ChemExpress 102
7.12.1 ChemExpress Profile 102
7.12.2 ChemExpress Main Business 103
7.12.3 ChemExpress Oligonucleotide Conjugates Products, Services and Solutions 104
7.12.4 ChemExpress Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025) 104
7.13 Creative Biolabs 105
7.13.1 Creative Biolabs Profile 105
7.13.2 Creative Biolabs Main Business 105
7.13.3 Creative Biolabs Oligonucleotide Conjugates Products, Services and Solutions 106
7.13.4 Creative Biolabs Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 108
7.14 HitGen 108
7.14.1 HitGen Profile 108
7.14.2 HitGen Main Business 109
7.14.3 HitGen Oligonucleotide Conjugates Products, Services and Solutions 109
7.14.4 HitGen Oligonucleotide Conjugates Revenue (US$ Million) & (2023-2025) 110
7.15 Pharmaron 110
7.15.1 Pharmaron Profile 111
7.15.2 Pharmaron Main Business 111
7.15.3 Pharmaron Oligonucleotide Conjugates Products, Services and Solutions 113
7.15.4 Pharmaron Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025) 113
7.16 Suzhou Biosyntech 114
7.16.1 Suzhou Biosyntech Profile 114
7.16.2 Suzhou Biosyntech Main Business 114
7.16.3 Suzhou Biosyntech Oligonucleotide Conjugates Products, Services and Solutions 115
7.16.4 Suzhou Biosyntech Oligonucleotide Conjugates Revenue (US$ Million) & (2024-2025) 116
7.17 Creative Biogene (IntegrateRNA) 116
7.17.1 Creative Biogene (IntegrateRNA) Profile 116
7.17.2 Creative Biogene (IntegrateRNA) Main Business 117
7.17.3 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Products, Services and Solutions 117
7.17.4 Creative Biogene (IntegrateRNA) Oligonucleotide Conjugates Revenue (US$ Million) & (2020-2025) 118
8 Industry Chain Analysis 119
8.1 Oligonucleotide Conjugates Industrial Chain 119
8.2 Oligonucleotide Conjugates Upstream Analysis 119
8.2.1 Key Raw Materials 119
8.2.2 Raw Materials Key Suppliers 120
8.3 Midstream Analysis 120
8.4 Downstream Analysis (Customers Analysis) 121
9 Research Findings and Conclusion 123
10 Appendix 125
10.1 Research Methodology 125
10.1.1 Methodology/Research Approach 125
10.1.2 Data Source 128
10.2 Author Details 131
10.3 Disclaimer 132